Imbria Pharmaceuticals is a clinical-stage company transforming the treatment of cardiovascular disease by targeting cardiac energy metabolism. The company’s focus is ninerafaxstat, a differentiated, first-in-class cardiovascular therapy. A pipeline-in-a-pill, it has broad potential utility by improving cardiac efficiency without negative effects on heart rate, rhythm, ejection fraction, or blood pressure. The U.S. Food and Drug Administration has granted Orphan Drug Designation to ninerafaxstat for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). 

Based in the Boston area, Imbria is backed by a leading syndicate of investors including RA Capital, SV Health Investors, Deep Track Capital, Catalio Capital Management, AN Ventures, BNP Paribas, and Cytokinetics.